| Phase 15 trials |
|
Phase 1
|
NCT05468346 |
Jul → Aug 2022 |
— |
Sunshine Lake Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07588646 |
Jun → Nov 2021 |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05383131 |
Jun → Nov 2021 |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04512170 |
Jul 2020 → Aug 2021 |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03092102 |
May 2017 → Feb 2019 |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT05139719 |
Feb 2023 → Dec 2026 expected |
interstitial lung disease |
Sunshine Lake Pharma Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05060822 |
Jun 2021 → Jul 2025 overdue |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07082842 |
Oct 2025 → Jan 2031 expected |
idiopathic pulmonary fibrosis |
Sunshine Lake Pharma Co., Ltd. |
Recruiting
|
No outcome recorded
|